Portfolio Company Vectron Biosolutions and Cytovance Biologics Partner to Improve Development of Biologics portfolioDynamk CapitalOctober 11, 2023
Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research portfolioDynamk CapitalSeptember 20, 2023
bit.bio and BlueRock Therapeutics announce collaboration to advance T cell (Treg) based therapies portfolioDynamk CapitalAugust 3, 2023
Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing portfolioDynamk CapitalJune 29, 2023
Virica Biotch To Expand Domestic Vaccine Manufacturing Capacity with Government Support portfolioDynamk CapitalApril 24, 2023
Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development through 3D spatial biology portfolioDynamk CapitalApril 12, 2023
Portfolio Company Vectron Biosolutions Recently Published in Frontiers in Chemical Engineering portfolioDynamk CapitalMarch 20, 2023
Curi Bio Names Nicholas Geisse, Ph.D., as New Chief Executive Officer portfolioDynamk CapitalFebruary 16, 2023
Portfolio Company BitBio Recently Announced a Partnership with Automata portfolioDynamk CapitalFebruary 10, 2023
Portfolio Company Envisagenics enters into Multi-Year Collaboration with BMS portfolioDynamk CapitalNovember 29, 2022
Portfolio Co. Vectron Biosolutions Partners with Plant-Based Foods Manufacturer portfolioDynamk CapitalOctober 26, 2022
Portfolio Co. RoosterBio and AGC Biologics Announce Collaboration portfolioDynamk CapitalAugust 23, 2022
Dynamk Capital Co-Leads $21M Vernal Biosciences round along with Ampersand Capital Partners portfolioDynamk CapitalJune 2, 2022
Bionter AG secures $3 Million in Series Seed Financing Led by Dynamk Capital portfolioDynamk CapitalApril 27, 2022
Portfolio Company Xcellbio expands Labcorp Collaboration for Cell & Gene Therapies portfolioDynamk CapitalApril 21, 2022
